Skip to content

VIN - Virtual Inversion in Neurorehabilitation "Modelling and piloting of a VR-supported physiotherapeutic home application for patients with chronic pain".

VIN - Virtual Inversion in Neurorehabilitation "Modelling and piloting of a VR-supported physiotherapeutic home application for patients with chronic pain". - VIN

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00031488
Enrollment
20
Registered
2023-05-15
Start date
2023-06-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain of the upper extremity R52.1 R52.2 R52.9

Interventions

Group 1: Inclusion criteria: - persistent upper limb pain with side emphasis for at least 3 months (exhausted diagnosis). - minimum age of =18 years - multimodal therapy/rehabilitation or surgical int

Sponsors

Institut für Gesundheits-und Pflegewissenschaften
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Persistent upper limb pain with side emphasis for at least 3 months (exhausted diagnosis). - Minimum age of =18 years - multimodal therapy/rehabilitation or surgical intervention at least 3 months ago - Sufficient vision - Independent coping with everyday life

Exclusion criteria

Exclusion criteria: - tumour-related pain - amputations - chronic facial pain or headaches - Conditions that make it impossible to understand the intervention goal (e.g. severe cognitive performance disorder)

Design outcomes

Secondary

MeasureTime frame
after 6 weeks: acceptance usage behaviour benefits risks feasibility

Primary

MeasureTime frame
pain experience: baseline and after 6 weeks, via visual analogue scale

Countries

Germany

Contacts

Public ContactSusanne Saal

University of Applied Sciences

susanne.saal@eah-jena.de?+49 1719204403

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026